Medicorp, Inc.

medicorpinc.com

Medicorp, Inc. is a nationwide physician recruiting company that was started in 1991. Now with over 2000 clients nationally we are one of the most seasoned and established companies you will find. Our physician recruiters have a combined 60+ years of invaluable consulting and physician placement experience that we are ready to put to work for you. Our focus and emphasis is and always has been on building long-term relationships with our clients and physicians.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

news image

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

news image

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More

Cell and Gene Therapy

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

news image

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More

Cell and Gene Therapy

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

news image

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More
news image

ARCTIC VISION ANNOUNCES US$32MN IN SERIES A TO EXPAND INNOVATIVE PRODUCT PORTFOLIO IN OPHTHALMOLOGY

Arctic Vision | July 15, 2020

Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, today announced its $32mn Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focuses on the development and commercialization of innovative ophthalmology therapies in China and Asia. The three investment institutions are actively investing in leading life science companies in the world with long term commitment.&...

Read More
news image

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More
news image

Cell and Gene Therapy

MUSC AND HELIX LAUNCH IN OUR DNA SC, FIRST-OF-ITS-KIND POPULATION GENOMICS PROGRAM TO DRIVE PREVENTIVE, PRECISION HEALTH CARE FOR SOUTH CAROLINIANS

Helix | September 21, 2021

The Medical University of South Carolina (MUSC) and Helix have announced a strategic collaboration to develop a first-of-its-kind population genomics initiative in South Carolina called In Our DNA SC. The large-scale program is designed to improve health care outcomes by integrating genetic insights into clinical care and research. The statewide initiative will enroll 100,000 patients in genetic testing over the next four years at no cost to the patient. The program will enable th...

Read More
news image

Cell and Gene Therapy

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Eliminate Noisy Oxygen Measurements in Bioreactors

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

Whitepaper

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Eliminate Noisy Oxygen Measurements in Bioreactors

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Making the Promise of mRNA a Reality: OvercomingScale-Up Challenges

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us